#glp-1-therapies

[ follow ]
#novo-nordisk #pharma-competition #drug-innovation #eli-lilly #weight-loss-and-diabetes-drugs
Healthcare
fromFortune
3 weeks ago

Novo Nordisk wants to keep its crown leading the weight loss drugs pack-despite outlook downgrades and lawsuits, its CFO has a plan | Fortune

Novo Nordisk faces declining sales and stock after GLP-1 competition; success depends on launching new products like Wegovy pill, CagriSema, and amycretin.
Healthcare
from24/7 Wall St.
3 months ago

Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions

Eli Lilly's GLP-1 weight-loss and diabetes drugs drove blockbuster sales and market leadership, making it a top-performing, high-valuation healthcare growth stock.
[ Load more ]